Acquisition of Immune Pharmaceuticals

Rhea-AI Summary

Immune Pharmaceuticals Inc (IMNPQ) has received an unconditional takeover offer from United General LTD (UK) to acquire its public company. The acquisition aims to facilitate a reverse merger with a large pharmaceutical entity post-approval from the SEC and bankruptcy court. This plan is designed to maintain the current public float, with intentions to update SEC filings promptly. However, risks exist regarding SEC and court approval, and uncertainties surround the completion of the merger agreement and potential challenges from third parties.

Positive

• Unconditional takeover offer from United General LTD to acquire Immune Pharmaceuticals.
• Plans for a reverse merger with a large pharmaceutical company post-takeover.
• Intention to bring the company current through SEC filings.

Negative

• Acquisition is subject to SEC and bankruptcy court approval, introducing uncertainty.
• No assurance that the merger agreement will be executed or approved.
• Potential challenges from third parties could disrupt the process.

Unconditional offer in relation to acquire the public entity

FORT LEE, VA / ACCESSWIRE / March 29, 2021 / Immune Pharmaceuticals Inc's (IMNPQ), (FZRQ.F) has received an unconditional offer to take over the public company.

Immune Pharmaceuticals Inc has today received an unconditional offer by United General LTD. (UK) to acquire control of Immune Pharmaceuticals Inc.'s public company.

The intent would be to reverse merge with a large pharmaceutical company once the takeover has completed.

The acquisition and substantial change of control will keep the existing public float in place after the change of control of the public entity has taken place, this will be reflected in the upcoming filings with the SEC.

United General's intention is to bring the public company current through filings with the SEC and then merge a new pharmaceutical project in to the company.

The proposal and legal direction of the new management team that has been discussed with the trustee for immune pharmaceuticals does not allow the new operating company to cancel exiting shares of the previous operating company's float.

The offer to acquire the Immune Pharmaceuticals public company is dependent on court and SEC approval. The process will begin in the coming days, It is United Generals intentions to begin filing with the SEC once possible.

Risks

There can be no assurance that any proposal will be accepted or approved by the SEC or by the bankruptcy court, and that any merger agreement can be executed or that any transactions with the trustee or legal council will be approved or consummated or challenged by any third party.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Immune Pharmaceuticals Inc

View source version on accesswire.com:
https://www.accesswire.com/637887/Acquisition-of-Immune-Pharmaceuticals

FAQ

What is the purpose of the acquisition offer for Immune Pharmaceuticals (IMNPQ)?

The acquisition aims to enable a reverse merger with a larger pharmaceutical company.

Who made the acquisition offer for Immune Pharmaceuticals?

The acquisition offer was made by United General LTD from the UK.

Is the acquisition of Immune Pharmaceuticals (IMNPQ) guaranteed?

No, the acquisition is subject to SEC and bankruptcy court approval, which is not guaranteed.

What are the risks associated with the acquisition of Immune Pharmaceuticals?

Risks include potential rejection by the SEC, court challenges, and uncertainties regarding the merger agreement execution.

What will happen to the public float of Immune Pharmaceuticals after the acquisition?

The existing public float will remain in place after the change of control.